You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
加科思-B(01167.HK):KRAS G12C抑制劑JAB-21822一期臨牀數據將在2022年美國臨牀腫瘤學會(ASCO)年會上發佈
格隆匯 05-27 23:00

格隆匯5月27日丨加科思-B(01167.HK)宣佈,公司將於2022年6月3日至6月7日召開的2022年美國臨牀腫瘤學會(ASCO)年會("2022 ASCO年會")上以壁報形式公佈KRASG12C抑制劑JAB-21822的一期臨牀數據。

研究摘要已於今日在ASCO官網發佈。

截至2022年1月28日,53位患者(中位年齡62歲,年齡區間為39-79歲)參與了五個不同劑量組的試驗,包括每日200毫克,每日400mg,每日800毫克,400毫克每日兩次及400毫克每日三次。其中共有33位患者(22例非小細胞肺癌、9例結直腸癌、2例胰腺癌)經歷過至少一次的治療後腫瘤評估。

 在每日400毫克和每日800毫克的劑量組中,非小細胞肺癌患者的客觀緩解率(ORR)和疾病控制率(DCR)分別是70%(7/10)和100%(10/10)。

 無劑量限制性毒性,在QD劑量組中,僅有一級和二級治療相關不良事件。

在KRAS G12C突變的實體瘤患者中,JAB-21822有良好的耐受性,並且具有顯著的有效性。這項臨牀試驗仍在進行中,以上數據截止日期為2022年1月28日。更新的數據將在2022 ASCO年會壁報上展示,請訪問 www.asco.org獲取更多信息。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account